Nuclear Medicine / Radiopharmaceuticals Market - Global Trends & Forecast to 2017

DUBLIN, June 27, 2013 /PRNewswire/ --

Research and Markets (http://www.researchandmarkets.com/research/9ksnpc/nuclear) has announced the addition of the "Nuclear Medicine/Radiopharmaceuticals [SPECT/PET Radioisotopes (Technetium, F-18)], [Beta/Alpha radiation therapy (I131, Y-90)], [Applications (Cancer/Oncology, Cardiac)] & Stable Isotopes (Deuterium, C-13) Market - Global Trends & Forecast to 2017" report to their offering.

     (Logo: http://photos.prnewswire.com/prnh/20130307/600769 )

The global radiopharmaceuticals market was valued at $3.8 billion in 2012 and is poised to reach $5.5 billion by 2017 at a CAGR of 7.8%.

A study conducted by the Organization for Economic Co-operation and Development (OECD) estimates that Tc-99m diagnostic procedures are expected to increase by 15% to 20% in mature markets such as Europe, North America, Japan, the Republic of Korea, and Oceania between 2010 and 2030. Radiopharmaceuticals in neurological applications such as Alzheimer's disease, Parkinson's disease and dementia are also being preferred by practitioners besides conventional treatment. Further, upcoming radioisotopes such as Ra-223 (Alpharadin) and Ga-68 possess huge potential for clinical applications. The scheduled shutdown of the NRU reactor in 2016 and OSIRIS in France in 2018 is, however, a major threat for manufacturers.

The therapy market is predominantly driven by its oncologic applications. Since conventional treatment procedures of cancer, surgery and chemotherapy have significant side effects, radioisotopes are being preferred by medical practitioners due to minimum or no side effects. The radiopharmaceutical therapy market is expected to grow significantly with the launch of the much-desired Alpharadin (Ra-223) in the near future. This isotope has tremendous potential to take up market share of beta emitters and brachytherapy.

Key Topics Covered:

1 Introduction

2 Executive Summary

3 Market Overview

4 Global Radiopharmaceuticals Market

5 Radiopharmaceuticals Market, by Application / Indication

6 Enriched Stable Isotopes Market

7 Geographic Analysis

8 Competitive Landscape

9 Company Profiles

Companies Mentioned

- Australian Nuclear Association And Technology Organization (Ansto)
- Board Of Radiation And Isotope Technology (Brit)
- Bracco Imaging S.P.A.
- Cambridge Isotope Laboratories, Inc.
- Cardinal Health, Inc.
- Covidien, Plc
- Eczacibasi-Monrol
- Fujifilm Holdings Corporation
- Ge Healthcare (Subsidiary Of General Electric Company)
- Iba Group 286
- Institute Of Atomic Energy Polatom Radioisotope Centre
- Institute Of Isotopes Co., Ltd.
- Institute Of Radioelement (Ire)
- Isotec, Inc. (Sigma-Aldrich)
- Lantheus Medical Imaging, Inc.
- Nordion, Inc.
- Ntp Radioisotopes (Pty), Ltd.
- Petnet Solutions, Inc. (A Subsidiary Of Siemens Medical Solutions Usa, Inc.)
- Rotem Industries, Ltd., Inc.
- Taiyo Nippon Sanso Corporation
- Urenco Limited

For more information visit http://www.researchandmarkets.com/research/9ksnpc/nuclear  

About Research and Markets
Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Research and Markets
Laura Wood, Senior Manager.
press@researchandmarkets.com
U.S. Fax: +1-646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Healthcare and Medical Devices

SOURCE Research and Markets